__

PWRM, Power 3 Medical Products Inc., PWRM.OB

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

PWRM recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

PWRM has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals.

As many as 5.3 million Americans are living with Alzheimer’s disease. Alzheimer’s destroys brain cells, causing memory loss and problems with thinking and behavior severe enough to affect work, lifelong hobbies or social life. Alzheimer’s gets worse over time, and it is fatal. Today it is the seventh-leading cause of death in the United States.

Alzheimer’s disease (AD) is the most common form of dementia, a general term for memory loss and other intellectual abilities serious enough to interfere with daily life. Alzheimer’s disease accounts for 50 to 80 percent of dementia cases.

Unless the disease can be effectively treated or prevented, the number of people with AD will increase significantly if current population trends continue. That’s because the risk of AD increases with age, and the U.S. population is aging. The number of people age 65 and older is expected to grow from 39 million in 2008 to 72 million in 2030, and the number of people with AD doubles for every 5-year interval beyond age 65.

PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).

PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrig’s disease), Alzheimer’s, Parkinson’s diseases, breast cancer, and drug resistance.

PWRM’s NuroPro Blood Test is diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease.

More about PWRM at www.power3medical.com

**************************************************************

MDT, Medtronic, Inc.

MDT develops, manufactures, and sells device-based medical therapies worldwide.

Heart failure occurs when the heart muscle is unable to pump effectively to meet the body’s need for blood and oxygen.

Heart failure is the only major cardiac disorder that is increasing in prevalence. Heart failure is the most costly cardiovascular disease in the United States at an estimated $40 billion per year. Heart failure accounts for more than one million hospitalizations annually, more than all forms of cancer combined.

** MDT reported the global launch of the Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial.

It is the industry’s first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation (SCS), or neurostimulation, to improve clinical signs and symptoms of heart failure.

More than 5 million Americans and 22 million people worldwide have heart failure and it is a leading cause of hospitalization. Heart failure stimulates the sympathetic nervous system further progressing the disease. The Defeat-HF study will evaluate whether SCS can restore the natural balance between the sympathetic and parasympathetic nervous systems to improve blood flow, reduce inflammation and restore the heart’s dimensions and function. The study will be conducted under an Investigational Device Exemption (IDE) in the United States.

Neurostimulation uses an implantable pulse generator (IPG), or neurostimulator, similar to a cardiac pacemaker, with a lead, or thin wire, connecting the device to the spinal cord to deliver low-intensity electrical pulses. The procedure includes percutaneous placement of the leads in the spinal column and the stop-watch-sized neurostimulator is typically implanted in the abdomen.

As the pioneer in neuromodulation, MDT’s technologies already have gained significant medical acceptance, including SCS for chronic back and leg pain, deep brain stimulation for movement disorders and sacral nerve stimulation for the debilitating symptoms of overactive bladder.

There are also neurostimulation therapies approved under Humanitarian Device Exemptions (HDEs) for severe obsessive-compulsive disorder and the nausea and vomiting associated with severe gastroparesis. There are more than 20 years of literature supporting SCS for cardiovascular applications.

More about MDT at www.medtronic.com

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).